EXAM 2021-22 PHARMACOLOGY

GENERAL PHARMACOLOGY

- 1. Determine the pharmacokinetic parameters
- 2. Determine the advantages of the sublingual route of administration
- 3. Determine the advantages of the rectal route of administration
- 4. Determine the mechanisms of drug absorption
- 5. Determine the peculiarities of drug absorption related to the pH of the environment
- 6. Determine the mechanisms of penetration of drugs through membranes and biological barriers
- 7. Determine the peculiarities of the passive diffusion of drugs
- 8. Determine the peculiarities of the active transport of drugs
- 9. Determine the peculiarities of the free form of drugs in the plasma
- 10. Determine the peculiarities of the bound form of drugs in the plasma
- 11. Determine the peculiarities of the volume of drug distribution
- 12. Determine the pathways of phase I of drug metabolism
- 13. Determine the pathways of phase II of drug metabolism
- 14. Determine the groups of drugs that are inducers of liver microsomal enzymes
- 15. Determine the groups of drugs that are inhibitors of liver microsomal enzymes
- 16. Determine the consequences of induction of hepatic microsomal enzymes
- 17. Determine the consequences of inhibition of hepatic microsomal enzymes
- 18. Determine the mechanisms of renal elimination of drugs
- 19. Determine the peculiarities of renal elimination of drugs depending on the pH of the urine
- 20. Determine the particularities of the half-life of the drugs
- 21. Determine the particularities of the primary action of the drug, pharmacodynamic action and overall pharmacological effect of drugs
- 22. Determine the typical mechanisms of action of drugs
- 23. Determine the phenomena of concomitant administration of drugs
- 24. Determine the phenomena of repeated administration of drugs
- 25. Determine the characteristics of the rebound effect
- 26. Determine the characteristics of the withdrawal syndrome
- 27. Determine the characteristics of the functional insufficiency while using drugs
- 28. Determine the safety parameters of the drugs
- 29. Determine the enzymes whose genetic polymorphism may alter the pharmacokinetics of drugs
- 30. Determine the enzymes whose genetic polymorphism may alter the pharmacodynamics of drugs
- 31. Determine the genetic polymorphism of enzymes involved in the phase II of drug metabolism
- 32. Determine the side effects of drugs on pregnancy
- 33. Determine the phenomena of drug addiction
- 34. Determine the definition of the therapeutic index
- 35. Determine the definition of the therapeutic range

VEGETOTROPIC DRUGS

- 1. Select the M-N-cholinomimetics with direct action
- 2. Select the M-N-cholinomimetics with indirect moderately reversible action
- 3. Select the M-N-cholinomimetics with indirect irreversible action
- 4. Select the M-cholinomimetics
- 5. Select the effects of M-N and M-cholinomimetics on the eye
- 6. Select the mechanisms of myosis in M cholinomimetics administration
- 7. Select the mechanisms of influence on intraocular pressure in M cholinomimetics administration
- 8. Select the effects of M-N and M-cholinomimetics on the digestive tract

- 9. Select the effects of M-N and M-cholinomimetics on the heart and bronchi
- 10. Select the effects of M-N and M-cholinomimetics on exocrine glands and urinary system
- 11. Select the symptoms of M-cholinomimetic intoxication
- 12. Select drugs used in intoxication with M-cholinomimetics
- 13. Select the symptoms of organophosphorus compound intoxication
- 14. Select the phases of organophosphorus compound intoxication.
- 15. Select drugs used in organophosphorus compound intoxication
- 16. Select the indications for M-cholinomimetics
- 17. Select the indications for anticholinesterases
- 18. Select the effects of N cholinomimetics
- 19. Select the M-cholinoblockers
- 20. Select the effects of M-cholinoblockers on the eye
- 21. Select the mechanisms of mydriasis in M cholinoblocker administration.
- 22. Select the mechanisms of influence on intraocular pressure in M cholinoblocker administration.
- 23. Select the effects of M-cholinoblockers on the digestive tract
- 24. Select the effects of M-cholinoblockers on the heart and bronchi
- 25. Select the effects of M-cholinoblockers on exocrine glands and urinary system
- 26. Select the symptoms of poisoning with M-cholinoblockers
- 27. Select the drugs used in poisoning with M-cholinoblockers
- 28. Select the indications for M-cholinoblockers
- 29. Select ganglioblockers with short, medium and long duration of action
- 30. Select the indications of the ganglioblockers
- 31. Select the side effects of ganglioblockers
- 32. Select the myorelaxants with antidepolarizing and depolarizing action
- 33. Select the mechanism of antidepolarizing action of myorelaxant drugs.
- 34. Select the mechanism of depolarizing action of myorelaxant drugs
- 35. Select the indications for myorelaxant drugs
- 36. Select the principles for decurarization of antidepolarizing and depolarizing myorelaxants
- 37. Determine the alpha-1-adrenoblocker drugs
- 38. Determine the beta-1-adrenoblocker drugs
- 39. Determine the beta-adrenoblocker drugs with vasodilating action
- 40. Determine non-selective beta-adrenoblocker drugs
- 41. Determine the alpha-beta-adrenoblocker drugs
- 42. Determine non-selective alpha-adrenoblockers
- 43. Determine the dopaminoblocker drugs
- 44. Determine the sympatholytic drugs
- 45. Determine the alpha-beta-adrenomimetic drugs
- 46. Determine the alpha-2-adrenomimetic drugs with peripheral action
- 47. Determine beta-2-adrenomimetic drugs
- 48. Determine beta-1-adrenomimetic drugs
- 49. Determine non-selective beta-adrenomimetic drugs
- 50. Determine alpha-1-adrenomimetic drugs
- 51. Determine alpha-2-adrenomimetic drugs with central action
- 52. Determine the adrenomimetic drugs that promote the release of mediators
- 53. Determine the adrenomimetic drugs that inhibit the reuptake of mediators
- 54. Determine adrenomimetic drugs with mixed mechanism of action
- 55. Determine the groups of adrenergic drugs that increase blood pressure
- 56. Determine the groups of adrenergic drugs that cause stimulating effects on the heart
- 57. Determine the groups of adrenergic preparations that lower blood pressure
- 58. Determine the groups of adrenergic preparations that produce bronchodilation
- 59. Determine the groups of adrenergic drugs that increase glucose levels

- 60. Determine the groups of adrenergic drugs that impair microcirculation
- 61. Determine the effects of alpha-beta-adrenomimetics on the heart
- 62. Determine the effects of alpha-beta-adrenomimetics on blood vessels
- 63. Determine the effects of alpha-beta-adrenomimetics on blood pressure
- 64. Determine the effects of alpha-adrenomimetics on blood pressure
- 65. Determine the effects of alpha-beta-adrenomimetics on microcirculation
- 66. Determine the effects of alpha-adrenomimetics on microcirculation
- 67. Determine the effects of alpha-beta-adrenomimetics on metabolism
- 68. Determine the effects of alpha-beta-adrenomimetics on the respiratory system
- 69. Determine the effects of beta-adrenomimetics on the heart
- 70. Determine the effects of alpha-adrenomimetics on blood vessels
- 71. Determine the effects of dopaminomimetics on the heart
- 72. Determine the effects of high-dose dopaminomimetics on blood vessels
- 73. Determine the effects of low-dose dopaminomimetics on blood vessels
- 74. Determine the effects of dopaminomimetics in medium doses on the heart
- 75. Determine the effects of beta-adrenomimetics on metabolism
- 76. Determine the effects of beta-adrenomimetics on the respiratory system
- 77. Determine the effect and mechanism of influence of alpha-adrenomimetics on the heart
- 78. Determine the effects of epinephrine on blood pressure
- 79. Determine the effects of norepinephrine on blood pressure
- 80. Determine how epinephrine differs from norepinephrine in their action on blood pressure
- 81. Determine the indications for alpha-beta-adrenomimetics
- 82. Determine the indications for alpha-adrenomimetics
- 83. Determine the indications for beta-2-adrenomimetics
- 84. Determine the indications for beta -1 -adrenomimetics
- 85. Determine the indications for dopaminomimetics
- 86. Determine the drugs used in hypotonic hypotension
- 87. Determine the drugs used in hypertonic hypotension
- 88. Determine the drugs used in anaphylactic shock
- 89. Determine the groups of drugs used in rhinitis, conjunctivitis
- 90. Determine preparations that cause tocolytic effect
- 91. Determine the side effects of alpha-beta-adrenomimetics
- 92. Determine the side effects of alpha-adrenomimetics
- 93. Determine the side effects of beta-adrenomimetics
- 94. Determine the side effects of beta-adrenoblockers
- 95. Determine the side effects of alpha-adrenoblockers
- 96. Determine the side effects of sympatholytics
- 97. Determine the mechanisms of action of sympatholytics.

DRUGS ACTING ON THE CNS.

- 1. Select volatile inhaled general anesthetics
- 2. Select gasses inhaled general anesthetics
- 3. Select the mechanisms of action of general anesthetics
- 4. Select groups of general intravenous anesthetics
- 5. Select short-action general intravenous anesthetics
- 6. Select medium-action intravenous general anesthetics
- 7. Select long-acting intravenous general anesthetics
- 8. Select groups of hypnotics
- 9. Select the hypnotics from the barbiturate group
- 10. Select the hypnotics from the benzodiazepine group
- 11. Select the hypnotics from the non-benzodiazepine group

- 12. Select the hypnotics from the melatonin agonists group
- 13. Select hypnotics with short duration of action
- 14. Select hypnotics with medium duration of action
- 15. Select hypnotics with long duration of action
- 16. Select the mechanisms of hypnotic action of barbiturates
- 17. Select the characteristics of the hypnotic effect of barbiturates
- 18. Select the characteristic effects of barbiturates
- 19. Select the barbiturates indications
- 20. Select side effects of barbiturates
- 21. Select the mechanisms of hypnotic action of benzodiazepines
- 22. Select the characteristics of the hypnotic effect of benzodiazepines
- 23. Select the characteristic effects of benzodiazepines
- 24. Select benzodiazepine indications
- 25. Select the side effects of benzodiazepines
- 26. Select the mechanisms of hypnotic action of non-benzodiazepines
- 27. Select the characteristics of the hypnotic effect of non-benzodiazepines
- 28. Select the non-benzodiazepines indications
- 29. Select the side effects of non-benzodiazepines
- 30. Select the mechanisms of hypnotic action of melatonin agonists
- 31. Select the characteristics of the hypnotic effect of melatonin agonists
- 32. Select the pleiotropic effects of melatonin agonists
- 33. Select the indications for melatonin agonists
- 34. Select melatonin receptor agonists as hypnotics
- 35. Select orexin receptor antagonists as hypnotics
- 36. Select the characteristics of orexin receptor antagonists as hypnotic
- 37. Select hypnotics used in disorders of falling asleep (the initial hyposomnia)
- 38. Select hypnotics used in nocturnal frequent wakings (intermittent hyposomnia)
- 39. Select hypnotics used in decreased duration of sleep or early awakening (terminal hyposomnia)
- 40. Select the groups of symptomatic anticonvulsants
- 41. Select the groups of symptomatic anticonvulsants that strongly inhibit the respiratory center
- 42. Select groups of symptomatic anticonvulsants that weakly inhibit the respiratory center
- 43. Select spasmolytics of skeletal muscles (central myorelaxants)
- 44. Select the characteristics of the muscle relaxant effect of benzodiazepines
- 45. Select the indications for benzodiazepines as central muscle relaxants
- 46. Select benzodiazepines used as central muscle relaxants
- 47. Select the drugs from various pharmacological groups used as the central muscle relaxants
- 48. Select the drugs used in major epileptic seizures
- 49. Select the drugs used in minor epileptic seizures
- 50. Select the drugs used in epileptic seizure (status epilepticus)
- 51. Select the drugs used in epileptic focal seizures
- 52. Select the mechanisms of action of antiepileptics
- 53. Select the groups of antiparkinsonian drugs
- 54. Select dopaminergic drugs as antiparkinsonian
- 55. Select cholinoblockers used as antiparkinsonian
- 56. Select the mechanisms of action of antiparkinsonian drugs
- 57. Select the types of local action of ethyl alcohol
- 58. Select the indications for ethyl alcohol in medicine
- 59. Select the consecutive order of influence of ethyl alcohol on the CNS
- 60. Select the effects of ethyl alcohol on the stomach depending on the concentration
- 61. Select metabolic changes in the liver under the action of ethyl alcohol
- 62. Select the peculiarities of ethyl alcohol absorption according to concentration
- 63. Select the peculiarities of the distribution of ethyl alcohol

- 64. Select the routes of metabolism of ethyl alcohol
- 65. Select the groups of drugs used in alcohol withdrawal syndrome
- 66. Select the groups of drugs used in the treatment of alcohol dependence
- 67. Select the peculiarities of the mechanism of action of disulfiram
- 68. Select the groups of antimicrobials that may cause a disulfiram reaction
- 69. Select the peculiarities of the mechanism of action of naltrexone in alcoholism
- 70. Select the groups of drugs used as sedatives
- 71. Select the indications for sedative drugs
- 72. Select the peculiarities of the sedative effect of herbal drugs
- 73. Select the groups of anxiolytic drugs
- 74. Select anxiolytics with a short duration of action
- 75. Select anxiolytics with a medium duration of action
- 76. Select anxiolytics with a long duration of action
- 77. Select the mechanism of action of benzodiazepine anxiolytics
- 78. Select the effects of anxiolytics
- 79. Select the indications for benzodiazepine anxiolytics
- 80. Select the side effects of benzodiazepine anxiolytics
- 81. Select the groups of typical antipsychotics
- 82. Select the groups of atypical antipsychotics
- 83. Select the peculiarities of the mechanism of action of antipsychotics
- 84. Select the effects of antipsychotics
- 85. Select the mechanism of the sedative effect of antipsychotics
- 86. Select the mechanism of the antipsychotic effect of antipsychotics
- 87. Select the indications for antipsychotics in psychiatry
- 88. Select the indications for antipsychotics in somatic diseases
- 89. Select side effects of antipsychotics on CNS
- 90. Select ophthalmic side effects of antipsychotics
- 91. Select endocrine side effects of antipsychotics
- 92. Select cardiovascular side effects of antipsychotics
- 93. Select the side effects of antipsychotics on digestive system
- 94. Select thymoisoleptic groups and drugs
- 95. Select the mechanisms of action of thymoisoleptics
- 96. Select the effects of thymoisoleptics
- 97. Select the indications of the normothymics
- 98. Select antidepressants that non-selectively inhibit monoamine reuptake
- 99. Select antidepressants that selectively inhibit serotonin reuptake
- 100. Select antidepressants that selectively inhibit norepinephrine reuptake
- 101. Select antidepressants that irreversibly inhibit monoamine metabolism
- 102. Select antidepressants that reversibly inhibit monoamine metabolism
- 103. Select the effects of antidepressants
- 104. Select the mechanism of action of heterocyclic antidepressants
- 105. Select other mechanisms of action (actions) of heterocyclic antidepressants
- 106. Select the mechanisms of action of antidepressants with action over the metabolism of monoamines
- 107. Select the central side effects of heterocyclic antidepressants
- 108. Select peripheral side effects of heterocyclic antidepressants
- 109. Select the side effects of MAOI antidepressants
- 110. Select cerebrovasoactive nootropics
- 111. Select the degroups of nootropic drugs
- 112. Select the mechanisms of action of nootropic drugs
- 113. Select the effects of nootropics
- 114. Select nootropic indications

- 115. Select nootropic si effects
- 116. Select the psychostimulants from the phenylalkylamine group
- 117. Select the psychostimulants from the piperidine group
- 118. Select the mechanisms of action of psychostimulants from the amphetamine group
- 119. Select the effects of psychostimulant drugs from phenylalkylamine group
- 120. Select the indications of psychostimulants
- 121. Select the adverse reactions of psychostimulants when using time is limited
- 122. Select the adverse reactions of psychostimulants in chronic abuse
- 123. Select the effects of psychostimulants from methylxanthines
- 124. Select the indications of psychostimulants from the methylxanthine group
- 125. Select the side effects of psychostimulants from methylxanthines in excessive doses
- 126. Select strong opioid analgesic agonists
- 127. Select the medium and weak agonists of opioid analgesics
- 128. Select opioid analgesic agonists-antagonists
- 129. Select opioid analgesic antagonists
- 130. Select centrally acting non-opioid analgesics
- 131. Select analgesics with mixed mechanism of action
- 132. Select analgesics with peripheral action
- 133. Select the mechanism of action of opioid analgesics at the systemic level
- 134. Select the levels of achievement of the analgesic action of opioid analgesics
- 135. Select the result of the action of opioid analgesics in the posterior horns of the spinal cord
- 136. Select the result of the action of opioid analgesics on the thalamus, hypothalamus, reticulated formation
- 137. Select the result of the action of opioid analgesics in the cerebral cortex
- 138. Select the actions of opioid analgesics on the psychic sphere
- 139. Select centers that are stimulated by opioid analgesics
- 140. Select centers that are inhibited by opioid analgesics
- 141. Select the effects of opioid analgesics on the digestive tract
- 142. Select the effects of opioid analgesics on the cardiovascular system
- 143. Select the effects of opioid analgesics on the respiratory system
- 144. Select the indications for opioid analgesics
- 145. Select the side effects of opioid analgesics from the CNS
- 146. Select the side effects of opioid analgesics from the digestive tract
- 147. Select the side effects of opioid analgesics from the respiratory system
- 148. Select the side effects of opioid analgesics from the urinary system
- 149. Select the mechanisms of action of paracetamol
- 150. Select the indications for paracetamol
- 151. Select the side effects of paracetamol
- 152. Select the mechanisms of action of tramadol
- 153. Select the indications for tramadol
- 154. Select side effects of tramadol
- 155. Select the mechanisms of action of peripherally acting analgesics
- 156. Select the effects of analgesics with peripheral action
- 157. Select the indications for peripherally acting analgesics

ANTITHROMBOTIC, HEMOSTATIC AND ANTIANEMIC

- 1. Determine groups of anticoagulants with direct action
- 2. Determine the groups of antiplatelet agents
- 3. Determine direct factor Xa antagonists
- 4. Determine direct thrombin antagonists
- 5. Determine heparinoids as anticoagulants

- 6. Determine the indirect anticoagulant drugs
- 7. Determine the antagonists of thromboxane A2 receptors
- 8. Determine the antiaggregant drug that inhibit phosphodiesterase
- 9. Determine the antiaggregant drugs that inhibit cyclooxygenase
- 10. Determine the antiaggregant drugs that block purinergic receptors
- 11. Determine the antiaggregant drugs that inhibit thromboxane synthase
- 12. Determine the antiaggregant drugs that reduce blood viscosity
- 13. Determine the antiaggregant drugs that block GPIIB / IIIA receptors
- 14. Determine the characteristic effects of standard heparin
- 15. Determine the mechanism of anticoagulant action of standard heparin
- 16. Determine the mechanism of anticoagulant action of low molecular weight heparins
- 17. Determine the mechanism of action of indirect anticoagulants
- 18. Determine the mechanism of antiplatelet action of clopidogrel
- 19. Determine the mechanism of antiplatelet action of acetylsalicylic acid
- 20. Determine the mechanism of antiplatelet action of pentoxifylline
- 21. Determine the mechanism of antiplatelet action of ridogrel
- 22. Determine the antiplatelet mechanism of abciximab
- 23. Determine the mechanism of antiplatelet action of dipyridamole
- 24. Determine the mechanism of antiplatelet action of prostaglandin analogues
- 25. Determine the peculiarities of acetylsalicylic acid as an antiplatelet agent
- 26. Determine the indications for standard heparin
- 27. Determine the indications for low molecular weight heparins
- 28. Determine the indications for sulodexide
- 29. Determine the indications for indirect anticoagulants
- 30. Determine the indications for indirect fibrinolytics
- 31. Determine indications for antiaggregant drugs
- 32. Determine the indications for dextrans as antithrombotics
- 33. Determine the side effects of standard heparin
- 34. Determine the groups and haemostatic drugs with systemic action
- 35. Determine the groups and haemostatic drugs with local action
- 36. Determine the indications for thrombin
- 37. Determine the indications for fibrinogen
- 38. Determine the indications for aprotinin
- 39. Determine the indications for synthetic antifibrinolytics
- 40. Determine the indications for calcium drugs as aggregants
- 41. Determine the indications for astringent drugs as hemostatic
- 42. Determine the indications for vasoconstrictor drugs as hemostatic
- 43. Determine the indications for vitamin K
- 44. Determine the mechanism of action of vitamin K
- 45. Determine the drugs used in haemolytic anemias
- 46. Determine the drugs used in hyperchromic anemias
- 47. Determine the drugs used in hypochromic anemia
- 48. Determine the drugs used in hypo- and aplastic anemias
- 49. Determine the indications for erythropoietin drugs
- 50. Determine the indications for iron drugs
- 51. Determine the effects of erythropoietin
- 52. Determine the drugs that stimulate leucopoiesis